Thrivent Financial for Lutherans
Position in APLS — Apellis Pharmaceuticals, Inc.
CIK 314984
Minneapolis, MN
Position in APLS
as of Mar 31, 2026
· filed May 1, 2026
Position Value
$0
+$0 QoQ
Shares Held
68,407
-30.0% QoQ
Ownership
0.053%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2023
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in APLS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Thrivent Financial for Lutherans holds $349,109,214 across 50 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | EXEL |
Exelixis, Inc.
|
1,620,743 | $88,184,625 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
131,457 | $81,968,697 | |
| 3 | RPRX |
Royalty Pharma plc
|
740,772 | $41,535,085 | |
| 4 | JAZZ |
Jazz Pharmaceuticals plc
|
80,500 | $19,398,084 | |
| 5 | ARGX |
Argenx SE
|
12,688 | $11,771,545 | |
| 6 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
20,169 | $10,018,546 | |
| 7 | VCEL |
Vericel Corp
|
170,272 | $7,575,400 | |
| 8 | KRYS |
Krystal Biotech, Inc.
|
17,229 | $6,403,502 |
All Filings in APLS
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | — | 68,407 | Shares | Sole | 2026-05-01 | |
| 2023-12-31 | — | 97,716 | Shares | Sole | 2024-02-14 | |
| 2023-09-30 | — | 79,461 | Shares | Sole | 2023-11-14 | |
| No filing history on record for this holder in this stock. | ||||||